Printer Friendly

Flex Pharma commences US phase two trial of Amyotrophic Lateral Sclerosis drug.

M2 PHARMA-August 3, 2017-Flex Pharma commences US phase two trial of Amyotrophic Lateral Sclerosis drug


United States-based Flex Pharma has started a phase two randomised, controlled, double-blinded, parallel design trial in the US, it was reported yesterday.

The COMMEND trial will assess FLX-787, the company's co-activator of TRPA1 and TRPV1, in patients with motor neuron disease, focused on Amyotrophic Lateral Sclerosis (ALS), who suffer from painful, debilitating cramps.

The FDA has granted the product Fast Track designation for the treatment of severe muscle cramps associated with ALS. The company expects to report topline results from this study in the middle of 2018. It also intends to start a Phase two clinical trial in associated disease, CMT, this quarter.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 3, 2017
Previous Article:Amgen and Allergan submit biologics license application for ABP 980 to US FDA.
Next Article:China Biologic reports Q2 2017 unaudited financial results.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters